Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT05324553 Recruiting - Cancer Clinical Trials

Patient Derived Preclinical Models

Start date: April 6, 2022
Phase:
Study type: Observational

Study goal is to collect tumor specimens that may inform cancer biology to eventually improve outcomes for patients with cancer. This proposal represents a highly collaborative effort to support cancer research with the goal of developing novel therapeutic strategies using patient derived preclinical models. This study is being done to collect samples of tumor tissues, matched normal tissue when possible, and approximately 50 mL of blood.

NCT ID: NCT05320588 Recruiting - Cancer Clinical Trials

A Study in Patients With Advanced Cancers

Start date: March 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

NCT ID: NCT05319925 Completed - Cancer Clinical Trials

Financial Effects of a Tumor Disease - Development and Validation of a Patient Reported Outcome Measure in Germany

FIAT
Start date: June 1, 2022
Phase:
Study type: Observational

This study aims to develop and to validate a standardised German-language instrument for measuring experienced financial effects of a cancer diagnosis and therapy in a cross-sectional bi-centre study. Obtained data will make the patient-related description of financial difficulties more comprehensible, communicable and addressable in the future, e.g. by offering targeted advisory aids or considering financial effects in health technology assessments.

NCT ID: NCT05318196 Recruiting - Cancer Clinical Trials

Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

NEPHROGENE2
Start date: September 5, 2022
Phase:
Study type: Observational

Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.

NCT ID: NCT05315908 Terminated - Obesity Clinical Trials

COVID-19 Testing in Underserved and Vulnerable Populations

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to enhance COVID-19 testing in three regional community health centers (CHCs) in San Diego County, California. In collaboration with CHC partners, their consortium organization, Health Quality Partners (HQP), investigators are pursuing the following Specific Aims: 1) Compare the effectiveness of automated calls vs text messaging for uptake of COVID-19 testing among asymptomatic adult patients with select medical conditions and those 65 years of age and older receiving care at participating CHCs. Secondarily, investigators will invite all study participants to receive flu vaccination and will assess feasibility and acceptability of study participants to refer adult family household members who are essential workers for COVID-19 testing. 2) Gather patient, provider, CHC leadership, and community stakeholder insights to establish best practices for future scale-up of COVID-19 testing sustainability and vaccination.

NCT ID: NCT05315895 Recruiting - Cancer Clinical Trials

The Dampness Syndrome of Chinese Medicine Cohort Study

DACOS
Start date: June 6, 2022
Phase:
Study type: Observational [Patient Registry]

The researchers plain to build a large-scale, longitudinal, prospective cohort characterized by TCM dampness syndrome. With the biobank of this cohort the investigators want to find the causality between TCM dampness syndrome and clinical chronic diseases and a new way to treat clinical disease.

NCT ID: NCT05313074 Completed - Cancer Clinical Trials

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

Start date: March 23, 2021
Phase: N/A
Study type: Interventional

Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.

NCT ID: NCT05312307 Withdrawn - Cancer Clinical Trials

Strata EXPress™: A Study Using StrataEXP™ to Identify RNA-Expression Biomarkers in Advanced Cancer Patients

StrataEXPress
Start date: February 6, 2023
Phase:
Study type: Observational

The primary goal of this study is to identify patients with RNA expression profiles consistent with eligibility requirements for therapeutic clinical trials across solid tumors. Left-over tumor tissue will be collected from eligible participants for RNA expression analysis using next-generation sequencing.

NCT ID: NCT05311709 Recruiting - Cancer Clinical Trials

Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities

SOLUCOM
Start date: May 30, 2022
Phase: Phase 2
Study type: Interventional

A single-arm, multicentre trial to investigate sotorasib in KRASG12C-mutated non-small cell lung cancer stage III/IV not amenable for curative treatment including patients with comorbidities, and to provide translational knowledge regarding mechanism of relapse and differences in responses, including differences among patients with different co-occurring mutations.

NCT ID: NCT05304988 Active, not recruiting - Cancer Clinical Trials

Development and Validation of the EFT for Adolescents With Cancer

Start date: September 7, 2020
Phase:
Study type: Observational

There is increasing evidence of interventions shown to be effective to promote physical activity in adolescents with cancer. Nevertheless, adolescents with cancer become physically inactive after the end of the interventions. These interventions emphasized heavily on interventionists' role to assess adolescents' physical fitness and prescribe exercises. After the intervention, the adolescents were unable to follow the previous exercise prescriptions due to their changing medical conditions. To promote physical activity sustainably, it is vital to develop a patient-based assessment tool to allow adolescents with cancer to self-assess their own appropriate levels of physical activity that they could perform. However, a review of literature indicates a lack of such a tool.